Running Title-Bone marrow metastasis in a neuroblastoma model 
Introduction
Neuroblastoma (NB), a peripheral neural crest-derived childhood solid tumor, is a major medical challenge (1, 2) . Half of all NB patients have metastatic disease at diagnosis which carries a poor prognosis. Primary human NB tumors arise in the paraspinal ganglia or the adrenal medulla, while disseminated disease appears in the bone marrow (BM, 71% of patients), bones (56%), lymph nodes (31%), lungs (3%) and other internal organs (15-45%). The new International Risk Group classification system of the disease divides the patients to 16 risk groups, with the highest risk group being the one that presents with metastasis to the BM and has only 40-50% survival rate (2, 3) . The most commonly used preclinical transgenic mouse NB model, the Th-MYCN model (4) exhibits a limited capacity for metastasis to the BM (< 5% incidence). In an attempt to establish an immunocompetent genetic metastatic model for NB we crossed two genetically engineered mouse lines, each with a known molecular alteration, common to the 
MYCN oncogene amplification is frequently seen in aggressive NB
and occurs in 25-35% of human patients (5) . Caspase-8 is a cysteine endoproteinase that cleaves peptide bonds after aspartic acids (6) . In addition to its proapoptotic function as an initiator caspase in the extrinsic receptormediated death pathway (6) , caspase-8 plays important roles in mediating migration, adhesion, growth, immune response, differentiation, wound healing, fibrosis and necroptosis in certain cell types (7) (8) (9) . Suppression of caspase-8 expression by epigenetic silencing occurs in ~70% of human neuroblastomas (10) . Loss of caspase-8 has also been associated with enhancement of the tumorigenic potential of SV40 T-antigen transformed mouse embryonic fibroblasts (11) and with providing an advantage in survival and metastasis of engrafted neuroblastoma cell lines (12, 13). Nevertheless, the role of caspase-8 expression has not been tested thus far in vivo in an immunocompetent mouse model which could have significance given the roles caspase-8 plays in the immune system.
To circumvent the lethality in CASP8 -/-mice, Salmena and coworkers developed a conditional knockout mouse in which LoxP sites were introduced into the DNA flanking exons 3 and 4 of the mouse caspase-8 gene (14) . We mated these mice with Th-Cre transgenic mice, which express Cre recombinase only in the peripheral neural crest cells and in the brain 6 catecholaminergic neurons starting on day E9.5 (15) , to selectively delete caspase-8 in the cells that give rise to neuroblastoma.
Our preliminary results suggested that conditional knockout of caspase-8 alone was insufficient to induce tumor formation. We studied 30 mice (129X1/SvJ background) harboring two floxed caspase-8 alleles and ThCre for 6-9 months. Tumors did not develop in any of these mice, suggesting that additional genetic alterations are needed. Thus, we tested the hypothesis that the loss of caspase-8 facilitates MYCN-induced tumor formation or metastasis by using the Th-MYCN transgenic mouse neuroblastoma model (4) . Since mouse genetic background influences tumor penetrance in this model (4), we backcrossed all mouse lines at least 6 generations (6-12) to the 129X1/SvJ background to ensure that differences in tumor formation were not due to strain variability.
Materials and Methods

Mouse strains
Th-MYCN hemizygote mice were purchased from NCI mouse repository (strain #01XD2) on genetic background 129X1/SvJ and kept on this background. Floxed caspase-8 mice were received from Razqallah Hakem (14) on 129X1/SvJ, C57BL6 background and backcrossed 6-12 generations to the 129X1/SvJ background. Th-Cre hemizygote mice were received from Dr.
Marcello Rubinstein (15) on a B6.CBF 2 background and backcrossed [6] [7] [8] [9] [10] [11] [12] generations to the 129X1/SvJ background. This study was carried out in strict 
Genotyping of mouse tissues and tumors
Caspase-8 primers:
Sense primer - .
Ultrasound imaging.
Ultrasound imaging of the mouse tumors was performed as described recently (16) using the VisualSonics VEVO-770 High frequency Ultrasound system (VisualSonics, Toronto, Canada).
Microarray analysis of neuroblastoma tumor samples
Total RNA was extracted from primary mouse tumors using Trizol reagent microRNA. Data was summarized by the RMA protocol (17) using Partek Genomics suite 6.6. Outlier samples were detected and removed by PCA and a batch correction corresponding to hybridization date was applied. The data was defined by class and a series of unequal variance t tests were applied to compare classes. Data was visualized and filtered by p value (0.05) and log ratio and submitted to Gene Set Enrichment Analysis (GSEA, http://www.broadinstitute.org/gsea) to assess Gene Ontology (GO) enrichment. The mRNAs targeted by downregulated microRNAs in the primary tumors samples with BM metastasis were predicted using MirTarget2 (18) , and followed by an enrichment analysis using DAVID at NIAID (19) .
All array data have been deposited in Gene Expression Omnibus at NCBI, and are accessible through GSE42548 (mRNA) and GSE42254 (microRNA).
Select array data was validated by qRT-PCR using TaqMan gene expression assays as described in Supplementary Fig. S1 .
Results
Establishing a neuroblastoma mouse model with MYCN amplification and caspase -8 deficiency
Neural crest-specific deletion of caspase-8 in mice was achieved by mating floxed and/or knockout caspase-8 alleles mice with hemizygous Th-Cre mice and then with hemizygous Th-MYCN mice (Fig. 1A) . Fig. S6 ).
Growth characterization of the primary neuroblastoma tumors in the genetically-engineered caspase-8 deficient Th-MYCN mouse model
Comparison of overall survival and primary tumor onset between the different mouse genetic groups, all on the 129X1/SvJ background, and harboring wild-type or deficient caspase-8 yielded no significant statistical difference ( Fig. 1E and Supplementary Fig. S4 ) with the limitation that all mice had to be sacrificed after 16-17 weeks due to high primary tumor burden.
To determine if there were any changes in the growth or location of the primary tumors prior to this point, we monitored weekly the tumors in both caspase-8-expressing and caspase-8-deleted Th-MYCN mice by ultra-sound imaging ( Fig. 2A) . No significant differences were found in the frequency or initial location of the tumors. Primary tumors in all mice groups were located in areas surrounding the aorta (81±7% in both groups) or near the adrenal gland or kidney (19±7% in both groups) ( Fig. 2A) . In addition, we examined mice at earlier time points (ages 10, 21, and 49 days) to determine whether there were variations in the number of initiating preneoplastic hyperplasia cells arising during development in the paraspinal ganglia (Fig. 2B) . These studies were based on previous work that showed higher frequencies of hyperplastic cells in the paraspinal ganglia of heterozygous Th-MYCN mice compared to 129X1/SvJ wild-type mice littermates 1-5 weeks after birth (20, 21) . These experiments as well did not reveal any differences in the appearance or incidence of hyperplastic neuroblasts between Th-MYCN mice with and without caspase-8 expression (Fig. 2B) , Thus, we conclude that caspase-8 deficiency does not significantly contribute to initial primary tumor formation.
Caspase-8 deficient Th-MYCN mice have preferentially enhanced neuroblastoma metastasis to the BM
We then screened Th-MYCN mice harboring advanced-stage primary tumors (ages 9-17 weeks, Fig. 3A ) from the wild-type and caspase-8-deficient groups for secondary metastatic tumors to determine whether caspase-8 plays a role in metastasis in vivo. Detailed necropsy of all major organs was performed ( Fig. 3B-3D ). In agreement with the data described above, no statistical significant difference was found in the average size of the initial primary tumors (Fig. 3A) . We did detect, however, a significant difference in the frequency of secondary tumors in the BM (Fig. 3B and Table 1 ). Eighty sections were cut from various bones of the mice, including the sternum, the long bones and the vertebra. Tumor cells were identified and the number of and 3D and Table 1 ). BM tumor cells were negative for caspase-8 expression as determined by immunostaining ( Supplementary Fig. S2 ) and had very low apoptosis levels (about 1%) measured by immunostaining for cleaved caspase-3 protein ( Supplementary Fig. S5 ). 
We compared the mRNA and microRNA expression profiles of a group of 6 primary tumors with wild type caspase-8 levels in animals with no BM metastasis to a group of 7 primary tumors with deficient caspase-8 levels in animals that had BM metastasis. Heat map of the top 20 statistically significant genes that differ in expression between the two groups are shown in Figure 4A ECM constituents changes as accumulation of collagens and laminins has been described in fibrosis of tissues and tumors (9, 34, 35, 37) and in wound response processes (8) . Caspase-8 down regulation has been linked to wound processes in vivo in which accumulation of collagen and other ECM structural proteins occur (8) and fibrosis is seen in mice that have deficient caspase-8 in their epidermal tissues (9) . In addition, caspase-8 has direct interaction with the ECM proteins by being in complexes with integrins (12, 46) and as a part of the focal adhesion complex (7). Deficiency of caspase-8 in the primary tumors thus could cause changes in the ECM structure and/or possible activation of a wound-like process that triggers deposition of ECM proteins by fibroblasts in the stroma and can activate production of various cytokines. The cytokine transforming growth factor β (TGF-β) is one of the major cytokines to be activated in response to wound/injury processes (47), fibrosis (36, 37) or as direct changes in the stiffness and mechnotransduction properties of the ECM (48).
Importantly for the BM preferential metastasis, TGF-β has been
shown by intravital imaging experiments to be transiently and locally Interestingly, we see upregulated expression in the caspase-8 deficient primary tumors of genes known to be induced by TGF-β as Tgif2 and Tgfβ1i1 (Table S1 ) and downregulation of miR-29b associated with TGF-β activation (36, 37) . Intravital imaging experiments in our caspase-8 deficient mouse model could shed light if indeed increased blood borne metastasis of single cells contributes to the preferred metastasis to the BM.
In this work we observed downregulation of microRNA-7 expression in the caspase-8 deficient mouse primary tumors which has been described recently in human neuroblastoma and was associated with metastatic advanced stage (38). 
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